The purpose of this study was to investigate the effect of gentamicin (100 mg/kg/day, i.p.) treatment on endothelium-dependent and -independent vasodilation in isolated perfused rat kidney, and the effect of amino acid L-arginine (in the drinking water, 2.25 g/l) on renal dysfunction induced by gentamicin. When gentamicin-treated groups were compared with the control group, it was observed that BUN and creatinine levels increased significantly. Also, the relaxant responses induced by acetylcholine, sodium nitroprusside and pinacidil decreased. Histopathological examination indicated acute tubular necrosis in this group. In animals treated with gentamicin together with L-arginine, there was a significant amelioration in the BUN and creatinine levels. The vasodilator responses were similar to those of the control group. Histopathological examination indicated only hydropic degeneration in tubular epithelium of kidney. Co-administration of L-NG-nitroarginine methyl ester (L-NAME) (112.5 mg/l), an inhibitor of nitric oxide synthase, and L-arginine to rats treated with gentamicin did not change the protective effect of L-arginine. In rats receiving L-NAME alone, the level of BUN and creatinine and vasodilation to acetylcholine were not significantly different when compared to those of the control group, while relaxant responses to sodium nitroprusside and pinacidil were increased. These results suggest that gentamicin leads to an impairment in vascular smooth muscle relaxation in addition to acute tubular necrosis in the rat kidney. Supplementation of L-arginine has an important protective effect on gentamicin-induced nephropathy.

Keywords:
Gentamicin, Nephrotoxicity, Renovascular relaxations, L-Arginine
1.
Mingeot-Leclercq MP, Tulkens PM: Aminoglycosides: Nephrotoxicity. Antimicrob Agents Chemother 1999;43:1003–1012.
2.
Kays SE, Crowell WA, Johnson MA: Iron supplementation increase gentamicin nephrotoxicity in rats. J Nutr 1991;121:1869–1875.
3.
Ben Ismail TH, Ali BH, Bashir AA: Influence of iron, deferoxamine and ascorbic acid on gentamicin-induced nephrotoxicity in rats. Gen Pharmacol 1994;25:1249–1252.
4.
Olbricht CJ, Fink M, Gutjahr E: Alterations in lysosomal enzymes of the proximal tubule in gentamicin nephrotoxicity. Kidney Int 1991;39:639–646.
5.
Bennett WM, Mela-Riker LM, Hougton DC, Gilbert DN, Buss WC: Microsomal protein synthesis inhibition: An early manifestation of gentamicin nephrotoxicity. Am J Physiol 1988;255:F265–F269.
6.
Conger JD, Robinette JB, Hammond WS: Differences in vascular reactivity in models of ischemic acute renal failure. Kidney Int 1991;39:1087–1097.
7.
Bachmann S, Bosse HM, Mundel P: Topography of nitric oxide synthesis by localizing constitutive NO synthases in mammalian kidney. Am J Physiol 1995;268:F885–F898.
8.
Baylis C, Harton P, Engels K: Endothelial derived relaxing factor controls renal hemodynamics in the normal rat kidney. J Am Soc Nephrol 1990;1:875–881.
9.
Tolins JP, Palmer RMJ, Moncada S, Raij L: Role of endothelium-derived relaxing factor in regulation of renal hemodynamic responses. Am J Physiol 1990;258:H655–H662.
10.
Radermacher J, Klanke B, Schurek HJ, Stolte HF, Frölich JC: Importance of NO/EDRF for glomerular and tubular function: Studies in isolated perfused rat kidneys. Kidney Int 1992;41:1549–1559.
11.
Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572–575.
12.
Can C, Şen S, Boztok N, Tuğlular I: Protective effect of L-arginine administration on gentamicin-induced renal failure in rats. Eur J Pharmacol 2000;390:327–334.
13.
Büyükafşar K, Yazar A, Düşmez D, Öztürk H, Polat G, Levent A: Effect of trapidil, on antiplatelet and vasodilator agent on gentamicin-induced nephrotoxicity in rats. Pharmacol Res 2001;44:321–328.
14.
Furchgott RF: Role of endothelium in responses of vascular smooth muscle. Circ Res 1983;53:557–573.
15.
Bhardwaj R, Moore PK: The effect of arginine and nitric oxide on resistance blood vessels of the perfused rat kidney. Br J Pharmacol 1989;97:739–744.
16.
Vargas F, Sabio JM, Luna JD: Contribution of endothelium-derived relaxing factors to acetylcholine-induced vasodilatation in the rat kidney. Cardiovsc Res 1994;28:1373–1377.
17.
Palmer RMJ, Ferrige AG, Moncada S: Nitric oxide release account for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524–526.
18.
Ignarro LJ, Lippton H, Edwards JC, Baricos WH, Hyman AL, Kadowitz PJ, Gruetter CA: Mechanism of smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: Evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 1980;214:9–15.
19.
Fan Z, Nakayama K, Hiraoka M: Pinacidil activates the ATP-sensitive K+ channel in inside-out and cell-attached patch membranes of guinea-pig ventricular myocytes. Pflügers Arch 1990;415:387–394.
20.
Palmer RMJ, Ashton DS, Moncada S: Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988;333:664–666.
21.
Gardiner SM, Compton AM, Bennett T, Palmer RMJ, Moncada S: Regional haemodynamic changes during oral ingestation of NG-monomethyl-L-arginine or NG-nitro-L-arginine methyl ester in conscious Brattleboro rats. Br J Pharmacol 1990;101:10–12.
22.
Wakabayashi Y, Kikawada R: Effect of L-arginine on myoglobin-induced acute renal failure in the rabbit. Am J Physiol 1996;270:F784–F789.
23.
Fickling S, Leone A, Nussey S, Vallance P, Whitley G: Synthesis of NG,NG-dimethylarginine by human endothelial cells. Endothelium 1993;1:137–140.
24.
Azuma H, Sato J, Hamasaki H, Sugimoto A, Isotani E: Obayashi S: Accumulation of endogenous inhibitors for nitric oxide synthesis and decreased content of L-arginine in regenerated endothelial cells. Br J Pharmacol 1995;115:1001–1004.
25.
May RC, Kelly RA, Mitch WE: Pathophysiology of uremia; in Brenner BM, Rector FC (ed): The kidney, ed 5. Philadelphia, Saunders, 1991, pp 1997–2018.
26.
Tojo A, Welch WJ, Bremer V, Kimoto M, Kimura K, Omata M, Ogawa T, Vallance P, Wilcox CS: Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int 1997;52:1593–1601.
27.
MacAllister RJ, Whitley GS, Vallance P: Effects of guanidino and uremic compounds on nitric oxide pathways. Kidney Int 1994;45:737–742.
28.
Cooke JP: Does ADMA cause endothelial dysfunction. Arterioscler Vasc Biol 2000;20:2032–2037.
29.
Keilstein JT, Böger RH, Bode-Böger SM, Frölich JC, Haller H, Ritz E, Fliser D: Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002;13:170–176.
30.
Ralevic V, Mathie RT, Alexander B, Burnstock G: NG-nitro-L-arginine methyl ester attenuates vasodilator responses to acetylcholine but enhances those to sodium nitroprusside. J Pharm Pharmacol 1991;43:871–874.
31.
Moncada S, Palmer MJ, Higgs EA: Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109–142.
32.
Adeagbo ASO, Triggle CR: Varying extracellular K+: A functional approach to separating endothelium-derived hyperpolarizing factor- and endothelium-derived nitric oxide-related mechanisms in perfused rat mesenteric arterial bed. J Cardiovasc Pharmacol 1993;21:423–429.
33.
Adeagbo ASO, Triggle CR: Effects of some inorganic divalent cations and protein kinase C inhibitors on endothelium-dependent relaxation in rat isolated aorta and mesenteric arteries. J Cardiovasc Pharmacol 1991;18:511–521.
34.
Nagao T, Illiano S, Vanhoutte PM: Heterogeneous distribution of endothelium-dependent relaxation resistant to NG-nitro-L-arginine in rats. Am J Physiol 1992;263:H1090–H1094.
35.
Cowan CL, Cohen RA: Two mechanisms mediate relaxation by bradykinin of pig coronary artery: NO-dependent and -independent responses. Am J Physiol 1991;261:H830–H835.
36.
Mieyal P, Fulton D, Mcgiff JC, Quilley J: NO-independent vasodilation to acetylcholine in the rat isolated kidney utilizes a charybdotoxin-sensitive, intermediate-conductance Ca2+-activated K+ channel. J Pharmacol Exp Ther 1998;285:659–664.
37.
Chauhan S, Rahman A, Nilsson H, Clapp L, Macallister R, Ahluwalia A: NO contributes to endothelium-derived hyperpolarizing factor-like responses in rat small arteries: A role for NO stores. Cardiovasc Res 2003;57:207–216.
38.
Featherston WR, Rogers QR, Freeland RA: Relative importance of kidney and liver in synthesis of arginine by the rat. Am J Physiol 1973;224:127–129.
39.
Reyes AA, Karl IE, Klahr S: Role of arginine in health and renal disease. Am J Physiol 1994;267:F331–F346.
40.
Radermacher J, Klanke B, Kastner S, Haake G, Schurek HJ, Stolte HF, Frölich JC: Effect of arginine depletion on glomerular and tubular kidney function: Studies in isolated perfused rat kidneys. Am J Physiol 1991;261:F779–F786.
41.
Chen C, Mitchell KD, Navar LG: Role of endothelium-derived nitric oxide in the renal hemodynamic response to amino acid infusion. Am J Physiol 1997;263:R510–R516.
42.
Ali BH, Bashir AK: Effect of superoxide dismutase treatment on gentamicin nephrotoxicity in rats. Gen Pharmacol 1996;27:349–353.
43.
Karataş Y, Seçilmiş MA, Karayaylalı İ, Doran F, Büyükafşar K, Şingirik E, Saglıker Y, Dikmen A: Effect of tempol (4-hydroxy tempo) on gentamicin-induced nephrotoxicity in rats. Fundam Clin Pharmacol 2004;18:79–83.
44.
Lass A, Suessenbacher A, Wolkart G, Mayer B, Brunner F: Functional and analytical evidence for scavenging of oxygen radicals by L-arginine. Mol Pharmacol 2002;1081–1088.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.